Novo Nordisk A/S (HAM:NOV) Common Stock : €60 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Novo Nordisk A/S Common Stock?

Novo Nordisk A/S's quarterly common stock increased from Sep. 2023 (€60 Mil) to Dec. 2023 (€61 Mil) but then declined from Dec. 2023 (€61 Mil) to Mar. 2024 (€60 Mil).

Novo Nordisk A/S's annual common stock declined from Dec. 2021 (€62 Mil) to Dec. 2022 (€61 Mil) and declined from Dec. 2022 (€61 Mil) to Dec. 2023 (€61 Mil).

Novo Nordisk A/S Common Stock Historical Data

The historical data trend for Novo Nordisk A/S's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Common Stock Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

64.26

63.18

62.13

61.29

60.51

Novo Nordisk A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															61.26	60.58	60.48	60.51	60.49

Novo Nordisk A/S Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Novo Nordisk A/S (HAM:NOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (HAM:NOV) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.